Tamoxifen, 17β-oestradiol and the calmodulin antagonist J8 inhibit human melanoma cell invasion through fibronectin

British Journal of Cancer

Volumn 75, Issue 6, 1997, Pages 860-868

  Dewhurst, L O ^a,b,c   Gee, J W ^a,b   Rennie, I G ^a,b   MacNeil, S ^a,b  

^a UNIVERSITY OF SHEFFIELD   (United Kingdom)

^b CARDIFF UNIVERSITY   (United Kingdom)

^c ROYAL HALLAMSHIRE HOSPITAL   (United Kingdom)

Author keywords

Calmodulin antagonists; Invasion; Melanoma; Oestrogen; Tamoxifen

Indexed keywords

4 HYDROXYTAMOXIFEN; ANTIESTROGEN; CALMODULIN INHIBITOR; ESTRADIOL; FIBRONECTIN; FULVESTRANT; NORTAMOXIFEN; TAMOXIFEN; ANTINEOPLASTIC AGENT; DRUG DERIVATIVE; N (8 AMINOOCTYL) 5 IODONAPHTHALENE 1 SULFONAMIDE; N-(8-AMINOOCTYL)-5-IODONAPHTHALENE-1-SULFONAMIDE; NAPHTHALENE DERIVATIVE; PROGESTERONE RECEPTOR; SULFONAMIDE;

ARTICLE; CANCER INVASION; CELL ADHESION; EXTRACELLULAR MATRIX; HUMAN; HUMAN CELL; MELANOCYTE; MELANOMA CELL; PRIORITY JOURNAL; CHEMISTRY; DRUG SCREENING; MELANOMA; METASTASIS; PATHOLOGY; SKIN TUMOR; UVEA TUMOR;

ANTINEOPLASTIC AGENTS; DRUG SCREENING ASSAYS, ANTITUMOR; ESTRADIOL; FIBRONECTINS; HUMANS; MELANOMA; NAPHTHALENES; NEOPLASM INVASIVENESS; RECEPTORS, PROGESTERONE; SKIN NEOPLASMS; SULFONAMIDES; TAMOXIFEN; UVEAL NEOPLASMS;

EID: 0030615039     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/bjc.1997.153     Document Type: Article

References (42)

1. Albini A and Colacci A ( 1993) Inhibition of malignant tumour cell invasion: an approach to anti-progression. Basic Life Sei 61: 335-350
2. Bedikian AY, Kantarjian H, Young SE and Bodey GP (1981) Prognosis in metastatic choroidal melanoma. 5 Med J 74: 574-577
3. Bouhoute A and Leclerq G (1992) Antagonistic effect of triphenylethylenic antioestrogens on the association of estrogen receptor to calmodulin. Biochein Biophys Res Comm 184: 1432-1440
4. Buzaid AC, Murren JR and Durivage HJ (1991) High dose cwplatin with dacarbazine and tamoxifen in the treatment of metastatic melanoma. Cancer 68: 1238-1241
5. 2+-calmodulin. Mol Emlocrinol 2: 167-174
6. Castoria G, Migliacco A, Green S, Di Domenico M, Chambon P and Aurrichio F (1993) Properties of a purified estradiol-dependent calf uterus tyrosine kinase. Biochemistry 32: 1740-1750
7. Cocconi G, Bella M, Calabresi F, Canaletti R, Boni C, Buzzi F, Ceci G, Costa E, Lottici R, Papdia F, Sofra MC and Bacchi M (1992) Treatment of metastatic malignant melanoma with dacarbazine plus tamoxifen. N Engl J hied 327: 516-523
8. Croxtall JD, Emmas C, White JO, Choudhary Q and Flower RJ-U994) Tamoxifen inhibits growth of oestrogen receptor-negative A549 cells. Biochem Pharinacol 47:197-202
9. Del Prete SA, Maurer LU, O'Donnell J, Jackson Forcier R and Le Marbre P (1984) Combination chemotherapy with a'jplatin, carmustine, dacarbazine and tamoxifen in mctastatic melanoma. Cancer Treat Rep 68: 1403-1405
10. Edward M and Mackie R (1993) Cell-cell and cell-ECM interactions during melanoma cell invasion and metastasis. Melanoma Res 3: 227-234
11. Feun LG, Savaraj N, Moffat F, Robinson D, Liebmann A, Hurley J, Raub WA, Jr and Richman SP (1995) Phase II trial of recombinant interferon-a with BCNU, r/'jplatin, DTIC and tamoxifen in advanced malignant melanoma. Melanoma Res 5: 273-276
12. Fierro MT, Bertero M, Novelli M, Appino A, Doveil GC, Cononna S and Bernengo MG ( 1993) Therapy for metastatic melanoma: effective combination of dacarbazine, carmustin, ciiplatin and tamoxifen. Melanoma Res 3: 127-131
13. Garbe C, Buttner P, Bertz J, Burg G, D'Hoedt B, Drepper H. Guggenmoos-Holzmann I, Lechner I, Lippold W, Orfanos A, Peters CE, Stadier R and Stroebel W (1995) Primary cutaneous melanoma. I. Identification of prognostic groups and estimation of individual prognosis for 5093 patients. Cancer 75: 2481-2491
14. Goodall T, Buffey JA, Rennie IG, Benson M, Parsons MA, Faulkner MK and MacNeil S ( 1994) Effect of melanocyte stimulating hormone on human cultured choroidal melanocytes, uveal melanoma cells and retinal epithelial cells. Invest Opthal Vis Sci 35: 826-837
15. Gragoudas ES, Egan KM, Seddon JM, Glynn RJ, Walsh SM, Finn SM, Munzennder JE and Spar MD (1991) Survival of patients with métastases from uveal melanoma. Opthalmology 98: 383-390
16. Gundimeda U, Chen Z-H and Gopalakrishna R (I996) Tamoxifen modulates protein kinase C via oxidative stress in estrogen receptor-negative breast cancer cells. JBiolChem 271: 13504-13514
17. Jordan VC, Wolf MF, Mirecki DM, Whitford DA and Welshons WV (1988) Hormone receptor assays: clinical usefulness in the management of carcinoma of the breast. Crir Ret- Clin Lab Sei 26:97-152
18. Karakousis CP and Driscoll DL (1995) Prognostic parameters in localised melanoma: gender versus anatomical location. Eur J Cancer 31:320-324
19. Legha S (1988) Interferon in the treatment of malignant melanoma. Biother Cancer I: 1-5
20. Maclay EF, Mastrangelo MJ, Sprandio JD, Bellet RE and Berd D (19S9) The importance of tamoxifen to a mplatin containing regime in the treatment of metastaticmelanoma. Cancer 63: 1293-1295
21. Maclay EF, Mastrangelo MJ, Berd D and Bellet RE (1992) Effective combination chemo/hormona! therapy for malignant melanoma: experience with three consecutive trials. Cancer 50:553-556
22. MacNeil S, Griffin M, Cooke AM, Pettett NJ, Dawson RA, Owen R and Blackburn CM (1988) Calmodulin antagonists of improved potency and specificity for use in the study of calmodulin biochemistry. Biochem Pharmacol 37: 1717-1723
23. MacNeil S, Wagner M, Wowk I, Doughty S, Brown J Beaumont J and Blackburn GM (1992) Intracellular regulation of cell adhesion to extracellular matrix components in murine B16 melanoma cells. Melanoma Res 2: 345-354
24. MacNeil S, Wagner M, Kirkham PR, Blankson EA, Lennard MS, Goodall T and Rennie IG (1993) Inhibition of melanoma cell/matrix interaction by tamoxifen. Melanoma Res 3: 67-74
25. MacNeil S, Wagner M and Rennie IG ( 1994) Investigation of the role of signal transduction in attachment to matrix proteins: inhibition of attachment by calmodulin antagonists including tamoxifen. Clin Exp Metastasis 12: 375-384
26. Markaverich BM, Gregory RR, Alejandro MA, Clark JH and Johnson GA (1988) An endogenous ligand for Type II binding sites. J Biol Chem 263: 7203-7210
27. Merkel DA and Osborne CK ( 1988) Use of steroid receptor assays in cancer management. Rev Endocr Rel Cancer 30: 5-12
28. Mortarini R and Anichini A ( 1993) From adhesion to signalling: roles of integrins in the biology of human melanoma. Melanoma Res 3: 87-97
29. Noguchi S, Motowura K, Inaji H, Imaoka S and Koyama II (1993) Down regulation of transforming growth factor-alpha by tamoxifen in human breast cancer. Cancer72: 131-136
30. O'Brian ÇA, Liskamp RM, Solomon DH and Weinstein IB (1985) Inhibition of protein kinase C by tamoxifen. Cancer Res 45: 2462-2465
31. Paul EV, Parnell BL and Fraker M ( 1962) Prognosis of malignant melanomas of the choroid and ciliary body. Inl Oplhalmol Clin 2: 387-402
32. Piantelli M, Maggiano N, Ricci R, Larocca LM, Capclli A, Scambia G, Isola G, Giorgio Natali P and Ranelletti FO (1995) Tamoxifen and quercetin interact with type II estrogen binding sites and inhibit the growth of human melanoma cells. J lin-est Dermatol 105: 248-253
33. Rajpal S, Moore R and Karakousis CP (1983) Survival in metastatic ocular melanoma. Cancer 52: 334-336
34. Reinigen D and Saba H (I993) Chemotherapy for stage 4 melanoma: a three year experience with mplatin, DTIC, BCNU and tamoxifen. Semin Stirg Oncol 9: 251-255
35. Rayter Z (1991) Steroid receptors in breast cancer. BrJSurg 78: 528-535
36. Shields JA, Augsbcrger JJ, Donosco LA, Bernardino VB Jr and Portenar M (1985) Hepatic metastasis and orbital recurrence of uveal melanoma after 42 years. Am J Opthalmol 100: 666-668
37. Stidham KR, Johnson JL and Seigler HF ( 1994) Survival superiority of females with melanoma: a multivariate analysis of 6383 patients exploring the significance of gender in prognostic outcome. Arch Surg 129: 316-324
38. Sutherland RL, Murphy LC, San Foo M, Green MD, Whybourne AM and Krozowski AM (1980) High-affinity anti-oestrogen binding site distinct from the oestrogen receptor. Nature 288: 273-275
39. Tomlinson S, Macneil S, Walker SW, Ollis ÇA, Merritt JE and Brown BL (1984) Calmodulin and cell function. Clin Sei 66:497-508
40. Van Leeuwen RL, Dekker SK, Arbiser JL, Vermeer BJ, Bruijn JA and Byers HR (1994) Phorbol ester induced rapid attachment and spreading of melanoma cell and the role of extracellular matrix proteins. Int J Cancer 57: 894-900
41. Vossaert KA, Silverman MK, Kopf AW, Bart RS, Rigal DS, Friedman RJ and Levenstein M (1992) Influence of gender on survival in patients with stage I malignant melanoma. J Am Acad Dermatol 26:429-440
42. Walker KJ, Bouzbar N, Robertson J, Ellis IO, Elston CW, Blarney RW, Wilson DW, Griffiths K and Nicholson RI (1988) Immunocytochemical localisation of estrogen receptor in human breast tissue. Cancer Res 50: 3545-3550